Physician profile
Jonathan Chun Oh
NPI 1215978051
$7,441.48
in general payments reported to CMS, 2019-2025
43 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,442 · 2020: $256 · 2022: $393 · 2023: $2,096 · 2024: $1,110 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853 · Consulting Fee: $1,839 · Travel and Lodging: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.19 |
| Consulting Fee | $1,839.17 |
| Travel and Lodging | $658.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $1,800.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,758.48 | 2023-2025 | Lynparza, Imfinzi, Enhertu |
| Glaxosmithkline, LLC. | $1,024.36 | 2023-2025 | Jemperli, Ojjaara |
| Stryker Corporation | $677.47 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $577.04 | 2022-2025 | Precisetumor, Myrisk |
| Clovis Oncology, INC. | $205.08 | 2020-2022 | |
| Biom'Up France Sas | $140.13 | 2020 | |
| Janssen Biotech, INC. | $129.28 | 2024-2025 | Rybrevant, Carvykti, Imbruvica |
| Merck Sharp & Dohme LLC | $106.16 | 2022-2025 | Keytruda, Welireg, Reblozyl |
| Incyte Corporation | $78.79 | 2020-2025 | Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $74.21 | 2025 | Enhertu, Datroway |
| Geron Corporation | $72.13 | 2025 | Rytelo |
| Genmab U.S., INC. | $52.79 | 2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $52.11 | 2025 | |
| Syndax Pharmaceuticals, INC. | $51.55 | 2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.